Is anyone aware of the drug Impaza, which encourages NO synthase, and might it be an applicable therapy for the penile and possibly testicular atrophy issue?
574 Effectiveness of combined therapy Impaza and PDE5 inhibitors in prophylaxis post-traumatic erectile dysfunction
Prophylaxis of erectile dysfunction in patients who had trauma urethra. We conducted the examination and treatment of 42 patients with trauma urethra without fractures of pelvic bones and interruption integrity of penile vessels complicated by stricture of urethra and who maintained erectile function. The examination included: IIEF questionnaire, clinical laboratory tests, physical examination, dopplerography of penile vessels, biopsy of cavernous bodies. All patients underwent surgical treatment of urethral stricture. Plastic surgery was performed for the first time, the history of the disease did not exceed 4-5 months. In order to prevent erectile dysfunction (ED) in patients with trauma of urethra, combined therapy was used with medications that improve oxygenation (raising the level of NO) of cavernous and spongy bodies (ultra small doses of antibodies to endothelial NO synthase (Impaza) and with inhibitors of phosphodiesterase type 5 in a dosage of 5 mg. Patients were divided into 2 groups: patients of the 1st group (n = 22) were on treatment in the clinic when the proposed the treatment approach was not used, and patients of the 2nd group (n = 20) received Impaza and phosphodiesterase 5 inhibitors type according to the developed protocol, protected by the patent of the Russian Federation No. 2308271, within 6 months. In patients of the 1 st group, ED of different degree severity was complicated in 77.2% of patients, in the 2nd group of ED only 15% of patients were registered. At the end of 8 months after trauma urethra and 3 months after the operation, the patients underwent biopsy cavernous bodies. Morphological study revealed that in the cavernous tissue of patients of the 2nd group, the walls of most caverns consisted of smooth muscle elements and were lined with endothelium, there were no signs of smooth muscle tissue atrophy. The walls of the caverns retained the scalloped condition, they were not deformed, whereas in the biopsy specimens of the cavernous bodies of the penis of patients of the 1 st group was noted the replacement of cavernous tissue by a mature fibrous connective tissue. Within 6 months after trauma of the urethra in the spongy tissue and the alveolar shell of the cavernous bodies, irreversible destructive-degenerative changes develop. Early, one month after the injury of the urethra, the administration of drugs that affect the endothelial NO - synthase (“Impaza”) and PDE 5 inhibitory drugs, can prevent erectile dysfunction. Work supported by industry: no.
Impaza and sildenafil: comparison of clinical effectiveness in patients with erectile dysfunction.
A blind, placebo-controlled, randomized trial showed clinical effectiveness of the preparation Impaza containing antibodies to endothelial NO synthase in ultralow doses. Impaza surpassed placebo, but was less potent than sildenafil in the ability to improve erectile function and other parameters characterizing sexual activity of men. Safety of Impaza was greater than that of other test preparations.
Effects of chronic treatment with the eNOS stimulator Impaza on penis length and sexual behaviors in rats with a high baseline of sexual activity.
Endothelial nitric oxide synthase (eNOS) has an important role in erection, and it also affects aspects of sexual behavior. In this experiment, we determined whether a compound enhancing the activity of eNOS, Impaza, could stimulate any aspect of sexual behavior and increase penis length in rats with a high baseline of sexual activity. For comparison, the PDE5 inhibitor sildenafil was included. Male rats were orally treated with Impaza or sildenafil for 28 days. Impaza (3 ml kg(-1)) was given daily while sildenafil (3 mg kg(-1)) was given twice weekly. Tests for sexual incentive motivation and copulatory behavior were performed just before drug treatment and at days 7, 14 and 28 of treatment. In addition, the length of the protruding penis at mount, intromission and ejaculation was measured. Impaza but not sildenafil increased penis length at mount after 14 and 28 days of treatment. The compounds failed to modify sexual incentive motivation or copulatory behavior. It is suggested that Impaza enhanced intracavernous pressure, as such a pressure increase is the most likely explanation for enhanced penis length at mount. This effect, together with an absence of motivational actions, suggests that Impaza may be the most valuable treatment for erectile dysfunction.